Elucidating the mechanism of Cam free live sex web xxx
Despite recent advances in basic and translational research in the field of cutaneous T cell lymphoma (CTCL) [1, 2], effective treatment options for advanced mycosis fungoides (MF) and Sézary syndrome (SS)—the two most common types of CTLC—are still limited.
Usually, conventional therapies result in only short-lived remissions [3,4,5].
Knockdown and knockout of LSD1 was achieved with sh RNA and CRISPR/Cas9, respectively, while the CRISPR/Cas9 synergistic activation mediator system was used to induce expression of endogenous HDACs and LSD1.
Furthermore, time-lapse fluorescence microscopy and an in vitro tubulin polymerization assay were applied.
Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL).
However, there is a need for further improvement of this therapeutic approach.
In particular, mutations in genes coding for proteins involved in histone modification (acetylation, methylation and ubiquitination) as well as chromatin remodeling were commonly detected .
The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression.
Indeed, the compound is also a potent microtubule-destabilizing agent.
Since time-lapse microscopy revealed that 4SC-202 could affect mitotic spindle formation, we performed an in vitro tubulin polymerization assay revealing that 4SC-202 can directly inhibit microtubule formation.
We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells.